Correct ImQE, the race against competition with a mean reduction in the genital lesion rate of only 42 percent below baseline has started. Everyone must be shaking in their boots
http://www.marketwatch.com/story/ge...-for-hsv-2-immunotherapy-at-idweek-2014-10-08
Vaxxas secures funding interest to see if professor Fraser utilizes nanopatch, page-58
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.02 |
Change
-0.480(4.17%) |
Mkt cap ! $233.8M | |||
| Open | High | Low | Value | Volume |
| $11.50 | $11.50 | $10.91 | $147.8K | 13.40K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 156 | $10.97 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.44 | 25 | 1 |
View Market Depth
| Last trade - 15.56pm 17/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |